This issue contains a comprehensive review of the most relevant information about targeted therapies, including preclinical studies as well as clinical trials that are ongoing. Attention is given to the main Tirosine Kinase inhibitors, such as anti-EGFR and multitargeted therapies. The newly developed therapies against intracellular pathways responsible for the tumor phenotype (mTOR inhibitors, farnesyltransferase inhibitors, and heat sock protein inhibitors) are also presented. This information is important because these ...
Read More
This issue contains a comprehensive review of the most relevant information about targeted therapies, including preclinical studies as well as clinical trials that are ongoing. Attention is given to the main Tirosine Kinase inhibitors, such as anti-EGFR and multitargeted therapies. The newly developed therapies against intracellular pathways responsible for the tumor phenotype (mTOR inhibitors, farnesyltransferase inhibitors, and heat sock protein inhibitors) are also presented. This information is important because these new drugs are being tested in the clinical setting
Read Less
Add this copy of Breast Cancer, an Issue of Hematology/Oncology Clinics to cart. $33.07, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2007 by Saunders.
